Mechanism
Acarbose inhibits alpha-glucosidase in the small intestine, reducing glucose absorption and delivering undigested carbohydrate to the colon. Combined with a high-fiber diet, this dramatically increases substrate for saccharolytic fermentation, boosting SCFA production (butyrate, propionate, acetate). The metabolic shift improves insulin sensitivity via GLP-1 signaling and reduces hepatic androgen production.
Rationale
PCOS is characterized by insulin resistance, hyperandrogenism, and gut dysbiosis with reduced SCFA producers. This intervention applies two-sided ecological engineering (Primitive 5) — the pharmaceutical component redirects nutrients to beneficial colonic fermenters, while the dietary component provides the substrate they need to outcompete pathobionts.
Evidence Status
- Clinical: Quasi-experimental studies show improved HOMA-IR, reduced testosterone, and improved menstrual regularity with acarbose in PCOS.
- Mechanistic: Acarbose increases colonic SCFA production and shifts microbiome composition toward saccharolytic taxa.
- Dietary synergy: High-fiber diets independently improve PCOS metabolic markers; combination effect appears synergistic.
Open Questions
- Optimal fiber type (resistant starch vs. soluble fiber) for maximal synergy with acarbose.
- Long-term adherence and GI tolerability of the combination.
- Whether microbiome changes persist after acarbose discontinuation.